Detalles de la búsqueda
1.
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 387(17): 1557-1568, 2022 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094839
2.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139273
3.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 25(5): 572-587, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38561010
4.
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
Med J Aust
; 220(2): 80-90, 2024 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212673
5.
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(5): 468-482, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37080223
6.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Lancet Oncol
; 24(11): 1196-1205, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37875144
7.
Comprehensive profiling identifies tumour and immune microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma.
Br J Dermatol
; 189(5): 588-602, 2023 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37470440
8.
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
Invest New Drugs
; 40(4): 782-788, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35435625
9.
A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy.
Support Care Cancer
; 30(5): 4243-4253, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35091845
10.
Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors.
Australas J Dermatol
; 63(1): 43-52, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34751431
11.
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Oncologist
; 26(9): e1508-e1513, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33942954
12.
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 379(4): 341-351, 2018 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863979
13.
Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy.
Transpl Infect Dis
; 23(3): e13531, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33249726
14.
Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol.
BMC Health Serv Res
; 21(1): 513, 2021 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34044840
15.
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Lancet Oncol
; 21(2): 294-305, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31952975
16.
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus.
Lancet Oncol
; 21(7): e350-e359, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32534633
17.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet
; 394(10212): 1915-1928, 2019 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31679945
18.
Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care.
Gynecol Oncol
; 157(3): 793-798, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32220419
19.
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Gynecol Oncol
; 159(2): 322-328, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32917410
20.
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
Future Oncol
; 16(18): 1235-1243, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32490686